Udenafil / Zydena®
Udenafil like Sildenafil, Tadalafil and Vardenafil
(Viagra®, Cialis® and Levitra® respectively) is an orally taken PDE-5 inhibitor.
Its function is very similar in that it blocks the action of phosphodiesterase
type 5 and relieves erectile dysfunction in men.
Udenafil is produced
by Dong-A PharmTech Co Ltd. from Korea and has actually been used there since
Nov 2005 and marketed as Zydena® and has since been approved for use in Russia
in 2008. An indication that it may indeed prove to be a factor in the ED medication
mix in the US one day.
News out in Nov
9th 2009 reveals that Dong-A- PharmTech Co Ltd and its US partner Warner Chilcott
have initiated phase 3 testing here in the United States. It includes approximately
1120 patients currently suffering from Erectile Dysfunction. These testing
will be double bind, randomized with a placebo to carefully study its effectiveness
and being careful not to show a bias.
Original
studies in Korea showed that in a 12 weeks scientific study that there
was a reported 92% penetration success rate versus 53% for the placebo. The overall
patient experience also was rated at a 89% satisfaction verses the placebo
satisfaction rate or 26%. It had a fairly rapid onset to be able to compete with
existing ED treatments and had a long duration of up to 24 hours. Side effects
reported where similar to Sildenafil or Tadalafil with some patients experiencing
skin flushing and or headache.
What benefit does a drug like Udenafil
have over Sildenafil, Tadalafil, Vardenafil or other experimental treatments
like Avanafil? It would be how it interacts with each individual. Udenafil would
provide an alternative to existing forms of treatment if accepted. Everyone's
body chemistry interacts differently on some scale with medications introduced.
For this reason, Udenafil may prove to "work better" for one individual over
another. Also related is someone's sexual profile and habits, the onset speed
and how long it lasts may favor someone over another. Clinically it has to be centered
on the patient along with follow up on how it seems to be working.
|
